ALLMedicine™ Multiple Myeloma Center
Research & Reviews 12,829 results
https://doi.org/10.1016/j.clinre.2022.102000
Clinics and Research in Hepatology and Gastroenterology; Carole S, Elena L et. al.
Aug 7th, 2022 - After several cases of peculiar hematological malignancies following introduction of new oral anti-hepatitis C virus (HCV) treatments in our recent practice, we aimed to systematically identify all cases of hematological malignancies (HM) in patie...
https://doi.org/10.1016/j.leukres.2022.106921
Leukemia Research; Shah N, Delforge M et. al.
Aug 6th, 2022 - To understand the experience of patients with relapsed and refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in the pivotal, phase 2 KarMMa...
https://doi.org/10.1097/RLU.0000000000004271
Clinical Nuclear Medicine; Marcus C, Schuster DM et. al.
Aug 6th, 2022 - Incidental concomitant second primary malignancy may be detected on PET/CT imaging. We present an 18F-fluciclovine PET/CT of a patient undergoing evaluation of biochemically recurrent prostate cancer with incidental radiotracer uptake within lytic...
https://doi.org/10.1182/bloodadvances.2022007291
Blood Advances; Kikuchi J, Kodama N et. al.
Aug 6th, 2022 - Extramedullary disease (EMD) is known to be associated with chemoresistance and poor prognosis in multiple myeloma (MM); however, the mechanisms of its development are not fully understood. Elucidating the mechanism of EMD development and its ther...
https://clinicaltrials.gov/ct2/show/NCT04445701
Aug 5th, 2022 - An open-label, multicenter, dose escalation study to evaluate the safety, tolerability and PK/pharmacodynamics of AO-176 in adults with relapsed/refractory multiple myeloma whose disease has progressed following at least 3 prior systemic lines of ...
Guidelines 36 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810475
Annals of Hematology; Henze L, Buhl C et. al.
Jan 8th, 2022 - Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy ...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.
Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...
https://doi.org/10.1016/j.clml.2021.07.028
Clinical Lymphoma, Myeloma & Leukemia; LeBlanc R, Bergstrom DJ et. al.
Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.
Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.
Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...
Drugs 168 results see all →
Clinicaltrials.gov 2,391 results
https://clinicaltrials.gov/ct2/show/NCT04445701
Aug 5th, 2022 - An open-label, multicenter, dose escalation study to evaluate the safety, tolerability and PK/pharmacodynamics of AO-176 in adults with relapsed/refractory multiple myeloma whose disease has progressed following at least 3 prior systemic lines of ...
https://clinicaltrials.gov/ct2/show/NCT04933539
Aug 5th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...
https://clinicaltrials.gov/ct2/show/NCT03338972
Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the safety of adoptive therapy with ex vivo expanded autologous CD8+ plus CD4+ T cells transduced to express a human B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) for patients with rel...
https://clinicaltrials.gov/ct2/show/NCT02465060
Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...
https://clinicaltrials.gov/ct2/show/NCT05297240
Aug 5th, 2022 - The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program in Spain between November 2019 and June 2021. S...
News 2,507 results
https://www.medscape.com/viewarticle/978095
Jul 27th, 2022 - New results with quadruple drug therapy in the frontline treatment of multiple myeloma (MM) are prompting experts to speculate that stem cell transplantation may soon be able to take a back seat in the treatment of newly diagnosed disease. “It is ...
https://www.medscape.com/viewarticle/977219
Jul 14th, 2022 - Only about 6% of cancer drugs tested in a phase 1 study in 2015 were ultimately approved by the US Food and Drug Administration (FDA) by 2021, a new analysis suggests. The researchers also found that about 8% of approved agents were subsequently t...
https://www.medscape.com/viewarticle/976709
Jul 7th, 2022 - The Centers for Medicare & Medicaid Services (CMS) has announced a new, voluntary alternative payment model, which will replace the Oncology Care Model (OCM) that ended on June 30. The OCM's successor, known as the Enhancing Oncology Model (EOM), ...
https://www.medscape.com/viewarticle/964339
Jul 5th, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael and welcome to Medscape InDiscussion: Multiple Myeloma. Today we're talking about triple-class refractory multiple myeloma. This is a particularly...
https://www.mdedge.com/fedprac/avaho/article/255829/multiple-myeloma/simultaneous-cases-carfilzomib-induced-thrombotic
Nathaniel J. Myall, MD, Samantha X. Wang, MD et. al.
Jun 28th, 2022 - As a class of drugs, proteasome inhibitors are known to rarely cause drug-induced thrombotic microangiopathy (DITMA). In particular, carfilzomib is a second-generation, irreversible proteasome inhibitor approved for the treatment of relapsed, refr.